Awakening guardian angels: drugging the p53 pathway

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase

Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,690

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites

Douglass, A. N., Kain, H. S., Abdullahi, M., Arang, N., Austin, L. S., Mikolajczak, S. A., Billman, Z. P., Hume, J. C. C., Murphy, S. C., Kappe, S. H. I., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.18 · Cited by 31

Targeted Nutlin-3A Loaded Nanoparticles Inhibiting P53–MDM2 Interaction: Novel Strategy for Breast Cancer Therapy

Das, M., Dilnawaz, F., & Sahoo, S. K. (2011) · Nanomedicine · doi:10.2217/nnm.10.102 · Cited by 31

Nanoparticle-mediated p53 gene therapy for tumor inhibition

Sharma, B., Ma, W., Adjei, I. M., Panyam, J., Dimitrijevic, S., & Labhasetwar, V. D. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-010-0008-9 · Cited by 31

Stochastic and Deterministic Models of Cellular p53 Regulation

Leenders, G. B., & Tuszyński, J. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00064 · Cited by 28

Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation

Dastidar, S. G., Raghunathan, D., Nicholson, J., Hupp, T. R., Lane, D. P., & Verma, C. S. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14345 · Cited by 30

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery

Thean, D., Ebo, J. S., Luxton, T., Lee, X. C., Yuen, T. Y., Ferrer, F. J., Johannes, C. W., Lane, D. P., & Brown, C. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-01712-5 · Cited by 31

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53

Sanhaji, M., Louwen, F., Zimmer, B., Kreis, N., Roth, S., & Yuan, J. (2013) · Cell Cycle · doi:10.4161/cc.24573 · Cited by 30

Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma

Tzaridis, T., Milde, T., Pajtler, K. W., Bender, S., Jones, D., Müller, S., Wittmann, A., Schlotter, M., Kulozik, A. E., Lichter, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11452 · Cited by 30

Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles

Yuen, T. Y., Brown, C. J., Xue, Y., Tan, Y. S., Ferrer‐Gago, F. J., Lee, X. C., Neo, J. Y., Thean, D., Kaan, H. Y. K., Partridge, A. W., et al. (2019) · Chemical Science · doi:10.1039/c9sc01456j · Cited by 30

STRA8–RB interaction is required for timely entry of meiosis in mouse female germ cells

Shimada, R., Kato, Y., Takeda, N., Fujimura, S., Yasunaga, K.-I., Usuki, S., Niwa, H., Araki, K., & Ishiguro, K.-I. (2023) · Nature Communications · doi:10.1038/s41467-023-42259-6 · Cited by 23

Replicated, replicable and relevant–target engagement and pharmacological experimentation in the 21st century

Kenakin, T., Bylund, D. B., Toews, M. L., Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.024 · Cited by 28

Oncolytic Vaccinia Virus: A Theranostic Agent for Cancer

Chen, N. G., & Szalay, A. A. (2010) · Future Virology · doi:10.2217/fvl.10.58 · Cited by 29

Actinomycin V Suppresses Human Non-Small-Cell Lung Carcinoma A549 Cells by Inducing G2/M Phase Arrest and Apoptosis via the p53-Dependent Pathway

Lin, S., Jia, F., Zhang, C., Liu, F.-Y., Ma, J., Han, Z., Xie, W., & Li, X. (2019) · Marine Drugs · doi:10.3390/md17100572 · Cited by 29

Evaluation of catacholase mimicking activity and apoptosis in human colorectal carcinoma cell line by activating mitochondrial pathway of copper(II) complex coupled with 2-(quinolin-8-yloxy)(methyl)benzonitrile and 8-hydroxyquinoline

Ali, A., Mishra, S., Kamaal, S., AlArifi, A. S., Afzal, M. F., Saha, K. D., & Ahmad, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104479 · Cited by 28

Discovery of MK-4688 : an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Reutershan, M. H., Machacek, M. R., Altman, M. D., Bogen, S. L., Cai, M., Cammarano, C., Chen, D., Christopher, M., Cryan, J. G., Daublain, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01524 · Cited by 29

Richter Syndrome

Rossi, D., & Gaïdano, G. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8051-8_8 · Cited by 29

Role of Adenoviruses in Cancer Therapy

Tseha, S. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.772659 · Cited by 32

A Conserved Mechanism for Binding of p53 DNA-Binding Domain and Anti-Apoptotic Bcl-2 Family Proteins

Lee, D., Ha, J., Kim, Y., Jang, M. K., Park, S. J., Yoon, H. S., Kim, E., Bae, K., Park, B. C., Park, S. G., et al. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0001 · Cited by 30

Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells

Gong, E.-Y., Shin, Y. J., Hwang, I.-Y., Kim, J. H., Kim, S.-M., Moon, J.-H., Shin, J.-S., Lee, D., Hur, D. Y., Jin, D.-H., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.06.019 · Cited by 29

Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation

Acar, H., Samaeekia, R., Schnorenberg, M. R., Sasmal, D. K., Huang, J., Tirrell, M., & LaBelle, J. L. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00364 · Cited by 28

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

Ciardullo, C., Aptullahoğlu, E., Woodhouse, L. C., Lin, W., Wallis, J. P., Marr, H. J., Marshall, S. R., Bown, N. P., Willmore, E., & Lunec, J. (2019) · Haematologica · doi:10.3324/haematol.2018.206631 · Cited by 28

RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status

Sonnemann, J., Grauel, D., Blümel, L., Hentschel, J., Marx, C., Blumrich, A., Focke, K., Becker, S., Wittig, S., Schinkel, S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.016 · Cited by 28

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201508416 · Cited by 29

Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Shahzad, M., Tariq, E. F., Chaudhary, S. G., Anwar, I., Iqbal, Q., Fatima, H., Abdelhakim, H., Ahmed, N., Balusu, R., Hematti, P., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2123228 · Cited by 32

A Novel p53 Phosphorylation Site within the MDM2 Ubiquitination Signal

Fraser, J. A., Madhumalar, A., Blackburn, E. A., Bramham, J., Walkinshaw, M. D., Verma, C. S., & Hupp, T. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.143107 · Cited by 29

Mirror image phage display – Generating stable therapeutically and diagnostically active peptides with biotechnological means

Sun, N., Funke, S. A., & Willbold, D. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.05.019 · Cited by 28

Modulating the p53 pathway

Dey, A., Lane, D. P., & Verma, C. S. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.004 · Cited by 27

Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.

Zheng, M., Yang, J., Xu, X., Sebolt, J. T., Wang, S., & Sun, Y. (2010) · PubMed · Cited by 28

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape

Subbiah, I. M., Tsimberidou, A. M., Subbiah, V., Jankú, F., Roy‐Chowdhuri, S., & Hong, D. S. (2017) · Oncoscience · doi:10.18632/oncoscience.352 · Cited by 28

p53 reactivation

D’Orazi, G., & Givol, D. (2012) · Cell Cycle · doi:10.4161/cc.21020 · Cited by 28

Multifaceted role of TRIM28 in health and disease

Maghsoudloo, M., Mokhtari, K., Jamali, B., Gholamzad, A., Entezari, M., Hashemi, M., & Fu, J. (2024) · MedComm · doi:10.1002/mco2.790 · Cited by 29

Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model

Maj, E., Filip‐Psurska, B., Świtalska, M., Kutner, A., & Wietrzyk, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126016 · Cited by 27

Investigating the Influence of Magnesium Ions on p53–DNA Binding Using Atomic Force Microscopy

Chen, Y., Gao, T., Wang, Y., & Yang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071585 · Cited by 27

The Disordered Linker in p53 Participates in Nonspecific Binding to and One-Dimensional Sliding along DNA Revealed by Single-Molecule Fluorescence Measurements

Subekti, D. R. G., Murata, A., Itoh, Y., Fukuchi, S., Takahashi, H., Kanbayashi, S., Takahashi, S., & Kamagata, K. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00292 · Cited by 26

Oridonin induces Mdm2‐p60 to promote p53‐mediated apoptosis and cell cycle arrest in neuroblastoma

Zhu, H., Zhang, C., Zhu-ying, G., Yang, J., Guo, J., Chen, C., Yao, Q., Liu, F., Zhang, Q., & Gao, F. (2019) · Cancer Medicine · doi:10.1002/cam4.2393 · Cited by 27

Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition

Shin, J., Ha, J., Lee, D.-H., Ryu, K., Bae, K., Park, B. C., Park, S. G., Yi, G., & Chi, S. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998056 · Cited by 27

Ral GTPase Down-regulation Stabilizes and Reactivates p53 to Inhibit Malignant Transformation

Tecleab, A., Zhang, X., & Sebti, S. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.565796 · Cited by 27

Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant

Lei, J., Qi, R., Wei, G., Nussinov, R., & Ma, B. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06538k · Cited by 27

Development of a Multifunctional Benzophenone Linker for Peptide Stapling and Photoaffinity Labelling

Wu, Y., Olsen, L. B., Lau, Y. H., Jensen, C. H., Rossmann, M., Baker, Y. R., Sore, H. F., Collins, S., & Spring, D. R. (2016) · ChemBioChem · doi:10.1002/cbic.201500648 · Cited by 26

Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme

Merlino, F., Daniele, S., Pietra, V. L., Maro, S. D., Leva, F. S. D., Brancaccio, D., Tomassi, S., Giuntini, S., Cerofolini, L., Fragai, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00004 · Cited by 27

p53 family members — important messengers in cell death signaling in photodynamic therapy of cancer?

Acedo, P., & Zawacka‐Pankau, J. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00251f · Cited by 27

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 27

Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics

Ji, B., Harris, B., Liu, Y., Deng, Y., Gradilone, S. A., Cleary, M. P., Liu, J., & Yang, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010093 · Cited by 26

Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening

Zheng, X. T., Goh, W. L., Yeow, P., Lane, D. P., Ghadessy, F. J., & Tan, Y. N. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.09.088 · Cited by 27

Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions

Musielak, B., Janczyk, W., Rodríguez, I., Plewka, J., Sala, D., Magiera‐Mularz, K., & Holak, T. A. (2020) · Molecules · doi:10.3390/molecules25133017 · Cited by 26

KRAS signaling in malignant pleural mesothelioma

Marazioti, A., Krontira, A. C., Behrend, S. J., Giotopoulou, G. A., Ntaliarda, G., Blanquart, C., Bayram, H., Iliopoulou, M. P., Vreka, M., Trassl, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013631 · Cited by 27

C-Terminal Substitution of MDM2 Interacting Peptides Modulates Binding Affinity by Distinctive Mechanisms

Brown, C. J., Dastidar, S. G., Quah, S. T., Lim, A., Chia, B. C. S., & Verma, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024122 · Cited by 26

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression

Palani, C. D., Beck, J. F., & Sonnemann, J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9510-7 · Cited by 26

The role of tripartite motif-containing 28 in cancer progression and its therapeutic potentials

Yang, Y., Tan, S., Han, Y.-Q., Huang, L., Yang, R., Hu, Z., Tao, Y., Oyang, L., Lin, J.-G., Peng, Q., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1100134 · Cited by 18

Genetic alteration profiling of patients with resected squamous cell lung carcinomas

Tao, D., Han, X., Zhang, N., Lin, D., Wu, D., Zhu, X., Song, W., & Shi, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9096 · Cited by 25

Targeting p53 in chronic lymphocytic leukemia

Moia, R., Boggione, P., Mahmoud, A. M., Kodipad, A. A., Adhinaveni, R., Sagiraju, S., Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1832465 · Cited by 25

Design, synthesis, antiproliferative activity, and cell cycle analysis of new thiosemicarbazone derivatives targeting ribonucleotide reductase

Ahmed, M. F. E., & Almalki, A. H. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.102989 · Cited by 25

Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma

Zhang, X., Pan, Q., Pan, K., Weng, D., Wang, Q., Zhao, J., He, J., Liu, Q., Wang, D., Jiang, S., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22259 · Cited by 25

Novel ARF/p53-independent senescence pathways in cancer repression

Chan, C., Gao, Y., Moten, A., & Lin, H. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0766-y · Cited by 25

Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure–Activity Relationship Studies and Pharmacological Activity

Giustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25

The hallmarks of ovarian cancer: proliferation and cell growth

López-Reig, R., & López-Guerrero, J. A. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.12.001 · Cited by 24

A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells

Geng, J., Goh, W. L., Zhang, C., Lane, D. P., Liu, B., Ghadessy, F. J., & Tan, Y. N. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00819k · Cited by 24

Detecting protein–protein interactions based on kinase-mediated growth induction of mammalian cells

Mabe, S., Nagamune, T., & Kawahara, M. (2014) · Scientific Reports · doi:10.1038/srep06127 · Cited by 24

Interventional Radiology and the Care of the Oncology Patient

O’Neill, S. B., O’Connor, O. J., Ryan, M. F., & Maher, M. M. (2011) · Radiology Research and Practice · doi:10.1155/2011/160867 · Cited by 24

Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer

Zhang, Y., Zhang, B., Zhang, A., Wu, T., LIU, J., Yu, L.-F., Wang, W., Gao, J., Fang, D.-C., & RAO, Z.-G. (2013) · Oncology Reports · doi:10.3892/or.2013.2663 · Cited by 24

The potential of miRNAs as biomarkers for multiple myeloma

Rocci, A., Hofmeister, C. C., & Pichiorri, F. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.946906 · Cited by 24

Flexibility is important for inhibition of the MDM2/p53 protein–protein interaction by cyclic β-hairpins

Danelius, E., Pettersson, M., Bred, M., Min, J., Waddell, M. B., Guy, R. K., Grøtli, M., & Erdélyi, M. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01510g · Cited by 25

Effective co-delivery of nutlin-3a and p53 genes via core–shell microparticles for disruption of MDM2–p53 interaction and reactivation of p53 in hepatocellular carcinoma

Davoodi, P., Srinivasan, M. P., & Wang, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00481h · Cited by 24

Somatic mutation analysis in melanoma using targeted next generation sequencing

Miraflor, A. P., Abreu, F. B. D., Peterson, J. D., Turner, S. A., Amos, C. I., Tsongalis, G. J., & Yan, S. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.08.006 · Cited by 24

Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM 4 and MDM 2 in colon and gastric cancer cells

Imanishi, M., Yamamoto, Y., Wang, X., Sugaya, A., Hirose, M., Endo, S., Natori, Y., Yamato, K., & Hyodo, I. (2018) · Cancer Science · doi:10.1111/cas.13893 · Cited by 24

Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2

Bueren‐Calabuig, J. A., & Michel, J. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004282 · Cited by 24

Sulphur alters NFκB-p300 cross-talk in favour of p53–p300 to induce apoptosis in non-small cell lung carcinoma

Saha, S., Bhattacharjee, P., Guha, D., Kajal, K., Khan, P., Chakraborty, S., Mukherjee, S., Paul, S., Manchanda, R. K., Khurana, A. K., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3061 · Cited by 23

Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer

Wong, K., Abascal, F., Ludwig, L., Aupperle‐Lellbach, H., Grassinger, J. M., Wright, C. W., Allison, S. J., Pinder, E., Phillips, R. M., Romero, L. P., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03026-4 · Cited by 24

Structural basis of how stress-induced MDMX phosphorylation activates p53

Chen, X., Gohain, N., Zhan, C., Lu, W.-Y., Pazgier, M., & Lu, W. (2015) · Oncogene · doi:10.1038/onc.2015.255 · Cited by 22

Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity

Gürlevik, E., Woller, N., Strüver, N., Schache, P., Kloos, A., Manns, M. P., Zender, L., Kühnel, F., & Kubicka, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.163 · Cited by 23

Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes

Gomes, N. P., & Espinosa, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12998 · Cited by 24

p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma

Supsavhad, W., Dirksen, W. P., Hildreth, B. E., & Rosol, T. J. (2016) · Veterinary Sciences · doi:10.3390/vetsci3030018 · Cited by 23

Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma

Catani, J. P. P., Medrano, R. F. V., Hunger, A., Valle, P. R. D., Adjemian, S., Zanatta, D. B., Kroemer, G., Costanzi-Strauss, E., & Strauss, B. E. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.09.011 · Cited by 24

Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells

Philippe, G. J.-B., Mittermeier, A., Lawrence, N., Huang, Y., Condon, N. D., Loewer, A., Craik, D. J., & Henriques, S. T. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00988 · Cited by 23

p53 mRNA Metabolism Links with the DNA Damage Response

Gnanasundram, S. V., Bonczek, O., Wang, L., Chen, S., & Fåhræus, R. (2021) · Genes · doi:10.3390/genes12091446 · Cited by 27

Niphateolide A: isolation from the marine sponge Niphates olemda and determination of its absolute configuration by an ECD analysis

Kato, H., Nehira, T., Matsuo, K., Kawabata, T., Kobashigawa, Y., Morioka, H., Losung, F., Mangindaan, R. E. P., de Voogd, N. J., Yokosawa, H., et al. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.07.009 · Cited by 23

Peptide Activators of the p53 Tumor Suppressor

Zhan, C., & Lu, W. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222577 · Cited by 23

Novel Isatin-based activator of p53 transcriptional functions in tumor cells.

Mirgayazova, R., Khadiullina, R., Mingaleeva, R. N., Chasov, V. V., Gomzikova, M. O., Garanina, E. E., Rizvanov, A. A., & Bulatov, E. (2019) · PubMed Central · doi:10.22099/mbrc.2019.34179.1419 · Cited by 22

Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-Like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents through the Modulation of SIRT6

Bellusci, L., Runfola, M., Carnicelli, V., Sestito, S., Fulceri, F., Santucci, F., Lenzi, P., Fornai, F., Rapposelli, S., Origlia, N., et al. (2020) · Molecules · doi:10.3390/molecules25051054 · Cited by 22

The pseudo-caspase FLIP(L) regulates cell fate following p53 activation

Lees, A., McIntyre, A. J., Crawford, N., Falcone, F., McCann, C. K., Holohan, C., Quinn, G. P., Roberts, J. Z., Sessler, T., Gallagher, P. F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001520117 · Cited by 22

CD80 expression is upregulated by TP53 activation in human cancer epithelial cells

Scarpa, M., Marchiori, C., Scarpa, M., & Castagliuolo, I. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1907912 · Cited by 22

Structure and Activity Analysis of Inauhzin Analogs as Novel Antitumor Compounds That Induce p53 and Inhibit Cell Growth

Zhang, Q., Ding, D., Zeng, S. X., Ye, Q.-Z., & Lu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046294 · Cited by 22

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells

Harajly, M., Zalzali, H., Nawaz, Z., Ghayad, S. E., Ghamloush, F., Basma, H., Zainedin, S., Rabeh, W., Jabbour, M. N., Tawil, A. N., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00747-15 · Cited by 24

Impact of Ser17 Phosphorylation on the Conformational Dynamics of the Oncoprotein MDM2

Bueren‐Calabuig, J. A., & Michel, J. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00127 · Cited by 22

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders

Citrin, R., Foster, J., & Teachey, D. T. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1216311 · Cited by 22

MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury

Thomasová, D., Ebrahim, M., Fleckinger, K., Li, M., Molnar, J., Popper, B., Liapis, H., Kotb, A. M., Siegerist, F., Endlich, N., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.390 · Cited by 21

In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines

Al‐Ghabkari, A., & Narendran, A. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2732 · Cited by 22

Mechanisms of protein misfolding: Novel therapeutic approaches to protein-misfolding diseases

Salahuddin, P., Siddiqi, M. K., Khan, S., Abdelhameed, A. S., & Khan, R. H. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.06.046 · Cited by 23

Adaptability in protein structures: structural dynamics and implications in ligand design

Maity, A., Majumdar, S., Priya, P., De, P., Saha, S., & Dastidar, S. G. (2014) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2013.873002 · Cited by 22

SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes

Herbert, K. J., Cook, A. L., & Snow, E. T. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.04.001 · Cited by 21

NEK9-dependent proliferation of cancer cells lacking functional p53

Kurioka, D., Takeshita, F., Tsuta, K., Sakamoto, H., WATANABE, S.-I. J., Matsumoto, K., Watanabe, M., Nakagama, H., Ochiya, T., Yokota, J., et al. (2014) · Scientific Reports · doi:10.1038/srep06111 · Cited by 21

Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer

Deng, F., Li, M., Shan, W., Qian, L.-T., Meng, S.-P., Zhang, X., & Wang, B. (2017) · Oncology Letters · doi:10.3892/ol.2017.5711 · Cited by 21

Blocking protein quality control to counter hereditary cancers

Kampmeyer, C., Nielsen, S. V., Clausen, L., Stein, A., Gerdes, A., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22487 · Cited by 21

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors

Kannan, S., Partridge, A. W., Lane, D. P., & Verma, C. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235996 · Cited by 21

MAGEA3 promotes proliferation and suppresses apoptosis in cervical cancer cells by inhibiting the KAP1/p53 signaling pathway.

Gao, X., Li, Q., Chen, G., He, H., & Ma, Y. (2020) · PubMed Central · Cited by 21

Interplay between Parkin and p53 Governs a Physiological Homeostasis That Is Disrupted in Parkinson's Disease and Cerebral Cancer

Checler, F., & da Costa, C. A. (2013) · Neurodegenerative Diseases · doi:10.1159/000354075 · Cited by 20

Global Effect of Inauhzin on Human p53-Responsive Transcriptome

Liao, J., Zeng, S. X., Zhou, X. Y., & Lu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052172 · Cited by 20

Identification of Polo-like kinases as potential novel drug targets for influenza A virus

Pohl, M. O., von Recum-Knepper, J., Rodríguez-Frandsen, A., Lanz, C., Yángüez, E., Soonthornvacharin, S., Wolff, T., Chanda, S. K., & Stertz, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08942-7 · Cited by 20

Downregulation of p53 promotes in vitro perineural invasive activity of human salivary adenoid cystic carcinoma cells through epithelial-mesenchymal transition-like changes

Yang, X., Jing, D., Liu, L., SHEN, Z., Ju, J., Ma, C., & Sun, M. (2015) · Oncology Reports · doi:10.3892/or.2015.3750 · Cited by 20

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68

ORIGINAL PAPER Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014)

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 675

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77